Stefan van den Eijnde
Director/Board Member at Dutch Vaccines Group
Profile
Stefan van den Eijnde is Director of Business Development for MUbio Products BV.
He co-founded NovoVacs BV in 2002.
Dr. van den Eijnde received a Master's degree in Biomedical Sciences from the University of Leiden in 1992 and a PhD in 1999.
Stefan van den Eijnde active positions
| Companies | Position | Start |
|---|---|---|
| Dutch Vaccines Group | Director/Board Member | 31/08/2009 |
| LifetecZONe | Director/Board Member | 16/05/2010 |
Former positions of Stefan van den Eijnde
| Companies | Position | End |
|---|---|---|
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Corporate Officer/Principal | 04/06/2013 |
| Maastricht University | Chief Tech/Sci/R&D Officer | - |
| NovoVacs BV | Founder | - |
Training of Stefan van den Eijnde
| University of Leiden | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
| NovoVacs BV | |
| Dutch Vaccines Group | |
| LifetecZONe |
- Stock Market
- Insiders
- Stefan van den Eijnde